Kim, Barbara

Case under preparation for upcoming board

Case under preparation for upcoming board

Case under preparation for upcoming board

61-year-old with extensive-stage SCLC, completed 4 cycles atezolizumab + carboplatin/etoposide with partial response. Prophylactic cranial irradiation (PCI) vs. MRI surveillance for brain metastases — discuss neurocognitive risk, patient is a retired engineer with strong preference to preserve cognitive function.

Limited-stage — concurrent chemoradiation with prophylactic cranial irradiation timing.

Relapsed SCLC — lurbinectedin vs. topotecan in platinum-sensitive vs. -resistant disease.

Limited-stage — concurrent chemoradiation with prophylactic cranial irradiation timing.

Limited-stage — concurrent chemoradiation with prophylactic cranial irradiation timing.

Limited-stage — concurrent chemoradiation with prophylactic cranial irradiation timing.

Relapsed SCLC — lurbinectedin vs. topotecan in platinum-sensitive vs. -resistant disease.

Limited-stage — concurrent chemoradiation with prophylactic cranial irradiation timing.

Limited-stage — concurrent chemoradiation with prophylactic cranial irradiation timing.

Relapsed SCLC — lurbinectedin vs. topotecan in platinum-sensitive vs. -resistant disease.

Extensive-stage — atezolizumab + carboplatin/etoposide vs. durvalumab + chemo first-line.

Limited-stage — concurrent chemoradiation with prophylactic cranial irradiation timing.